A few notes below. I hate to say it, but IMHO the algorithms in the previous 2 versions were clearer.
1.
They redefine urgency and risk.
Emergent procedure= threat to life or limb if not in OR < 6 hours, no/very limited/minimal clinical evaluation.
Urgent procedure = threat to limb or life if not in the OR in 6-24 hours, time for limited clinical evaluation.
Time-sensitive procedure (most oncologic procedures) = a delay of >1-6 weeks to allow for an evaluation and significant changes in management will negatively affect outcome.
Elective procedure = could be delayed up to 1 year.
Low risk procedure = risk of major adverse cardiac event (MACE) or MI of <1%.
Elevated risk procedure = risk of MACE > 1%.
2. Clinical Risk Factors: Recommendations
1. Valvular Heart Disease
- If patient has at least moderate valvular stenosis or regurg -> preop echo, if no preop echo within 1 year or change in clinical status or physical exam since last evaluation
- If patient meets standard indications for valvular intervention (replacement and repair) on the basis of symptoms and severity, valvular intervention before elective non-cardiac surgery will reduce periop risk.
-
Elevated-risk noncardiac surgery with intraop and postop hemodynamic monitoring is reasonable to perform in patients with asymptomatic severe AS/MR , asymptomatic severe AR with normal LVEF. or asymptomatic severe MS if valve morphology is not favorable for perc mitral balloon commissurotomy.
2. Other clinical risk factors
- Chronic pulmonary vascular targeted therapy should be continued, unless contraindicated/not tolerated, in patients with PHTN for noncardiac surgery.
- Unless the risks of the delay outweigh the potential benefits, preop evaluation by a PHTN specialist before noncardiac surgery can be beneficial, particularly for those with features of increased periop risk
3.2
Stepwise approach to CAD (known or risk factors for):
1. If emergency -> clinical risk stratification (that may influence periop management) and proceed to surgery with appropriate monitoring.
2. If surgery urgent/elective and ACS -> refer for cardiology eval and mgmt according to GDMT (goal-directed medical therapy) according to UA/NSTEMI and STEMI CPGs (clinical practice guidelines)
3. If risk factors for stable CAD -> estimate periop risk of MACE on the basis of the combined clinical/surgical risk. This can use the ACS NSQIP risk calculator (
www.surgicalriskcalculator.com) or incorporate the RCRI.
4. If risk of MACE <1% -> proceed to surgery without further testing.
5. If elevated risk of MACE (>1%), determine functional capacity with an objective measure or scale, such as the DASI (Duke Activity Status Index). If moderate/good/excellent (>= 4 METs) functional capacity, proceed to surgery without further eval.
6. If poor (< 4 METs) or unknown functional capacity -> pharmacological stress testing if it will impact patient decision making or periop care. If unknown functional capacity, exercise stress testing reasonable to perform. If stress test abnormal, consider coronary angiography and revascularization; the patient can then proceed to surgery with GDMT, or consider alternative strategies, such as noninvasive treatment for the indication of surgery, or palliation. If stress test is normal, proceed to surgery according to GDMT.
7. If testing will not impact decision making or care, proceed to surgery according to GDMT or consider alternative strategies, such as noninvasive treatment for the indication of surgery or palliation.
4.1 The 12-Lead ECG
- Preop resting ECG is reasonable for patients with known CAD, significant arrhythmia, peripheral arterial disease, cerebrovascular disease, or other significant structural heart disease, except if low-risk surgery.
- Preop resting ECG may be considered for asymptomatic patients without known CAD, except for low-risk surgery.
- Routine preop resting 12-lead ECG not useful for asymptomatic patients undergoing low-risk procedures.
4.2 Assessment of LV function
- Reasonable for patients with dyspnea of unknown origin to undergo preop eval of LV fxn.
- Reasonable for patients with HF with worsening dyspnea or other change in clinical status to undergo preop eval of LV fxn.
- Reassessment of LV fxn in clinically stable patients with previous LV dysfxn may be considered if previous assessment > 1 year ago.
- Routine preop eval of LV fxn not recommended.
4.3 Exercise testing
- If elevated risk and >10 METs, reasonable to forgo further exercise testing with cardiac imaging, and proceed to surgery.
- If elevated risk and unknown FC, reasonable to perform exercise testing for FC if it will change management.
- If elevated risk and 4-10 METs, may be reasonable to forgo further exercise testing with cardiac imaging, and proceed to surgery.
- If elevated risk and <4 METs or unknown FC, reasonable to perform exercise testing with cardiac imaging if it will change management.
- Routine screening with noninvasive stress testing not useful for low risk patients.
4.4. Noninvasive Pharmacological Stress Testing Before Noncardiac surgery
- If elevated risk and <4 METs, noninvasive pharmacological stress testing reasonable, if it will change management.
- Routine screening with noninvasive stress testing not useful for low-risk noncardiac surgery.
5.1. Coronary Revascularization Before Noncardiac Surgery
- Recommended if indicated according to existing CPGs (2011 CABG and 2011 PCI CPGs)
- Not recommended routinely before noncardiac surgery exclusively to reduce periop cardiac events.
5.2. Timing of Elective Noncardiac Surgery in Patients With Previous PCI
- Elective noncardiac surgery should be delayed 14 days after balloon angioplasty.
- Elective noncardiac surgery should optimally be delayed 365 days after DES.
- Consensus decision among treating physicians about risks of surgery and antiplatelet therapy.
-
Elective noncardiac surgery after DES can be considered after 180 days, if the risk of further delay is greater than the risk of ischemia and stent thrombosis.
- Elective noncardiac surgery should not be performed within 30 days after BMS, or 12 months after DES if dual antiplatelet therapy will need to be discontinued periop.
- Elective noncardiac surgery should not be performed within 14 days of balloon angioplasty if aspirin will need to be discontinued periop.
5.3. Periop Beta-Blocker Therapy
- Should be continued in patients who are on BB chronically.
- Reasonable if intermediate- or high-risk myocardial ischemia noted in preop risk stratification, or if >=3 RCRI risk factors
- Should not be started on the day of surgery.
5.4, 5.5, 5.6.
- Statins should be continued.
- Statins for vascular surgery reasonable to start periop.
- Alpha-2 agonists not recommended for prevention of cardiac events in noncardiac surgery.
- Reasonable to continue ACEI/ARB. If stopped, should be restarted ASAP postop.
5.7. Antiplatelet Agents
- If 4-6 weeks after BMS/DES, dual antiplatelet tx should be continued, unless the relative risk of bleeding outweighs the benefit of prevention of stent thrombosis
- If on P2Y12 platelet receptor-inhibitor, aspirin should be continued and the P2Y12 restarted ASAP postop.
- Management of periop antiplatelet tx by consensus of surgeon, anesthesiologist, cardiologist and patient, risk of bleeding versus prevention of stent thrombosis
- If no previous coronary stenting, reasonable to continue aspirin if risk of cardiac events > risk of increased bleeding.
- If no previous coronary stenting, initiation/continuation of aspirin not beneficial unless risk of ischemic events > risk of surgical bleeding.
5.8. CIEDs
-
If preop reprogramming to prevent tachytherapy, patients should be on cardiac monitoring and external defibrillator should be available. CIED should be reprogrammed to active therapy before discontinuation of cardiac monitoring and discharge.
6. Anesthetic Consideration and Intraop Management
-
Use of PAC may be considered when underlying medical conditions that significantly affect hemodynamics cannot be corrected before surgery.
- No benefit for routine use of PAC, even in patients with elevated risk.